8-K: P3 Health Partners Reports Full Year 2024 Results: Revenue Up 18%, Affirms 2025 Guidance

P3 Health Partners announces an 18% increase in revenue for 2024, reaching $1.50 billion, while affirming its financial outlook for 2025.

Summary

• P3 Health Partners reported its financial results for the fourth quarter and full year ended December 31, 2024.
• Full-year revenue increased by 18% year-over-year to $1.50 billion.
• The company affirmed its 2025 guidance.
• Fourth-quarter revenue increased by 7% to $370.7 million compared to $346.9 million in the prior year.
• Full-year at-risk membership increased by approximately 14% to 123,800.
• The company reported a net loss of $310.4 million for the full year, compared to a net loss of $186.4 million in the prior year.
• Adjusted EBITDA loss for the full year was $167.2 million, compared to an Adjusted EBITDA loss of $85.5 million in the prior year.
• The company is guiding for 2025 total revenues between $1.35 billion and $1.50 billion.
• The company is guiding for 2025 medical margin between $174 million and $210 million.
• The company is guiding for 2025 Adjusted EBITDA between $(35) million and $5 million.

Sentiment

Score: 4

Explanation: While revenue growth is positive, increasing losses and concerns about financial sustainability temper the overall sentiment.

Positives

• Revenue increased by 18% year-over-year to $1.50 billion.
• At-risk membership increased by approximately 14% to 123,800.
• The company is affirming its 2025 revenue guidance of $1.35 billion to $1.50 billion.
• The company identified $130M+ in programmatic opportunities advancing their path to financial sustainability.

Negatives

• Gross profit was a loss of $58.9 million for the full year, compared to a profit of $31.6 million in the prior year.
• Net loss was $310.4 million for the full year, compared to a net loss of $186.4 million in the prior year.
• Adjusted EBITDA loss was $167.2 million for the full year, compared to an Adjusted EBITDA loss of $85.5 million in the prior year.
• Medical margin decreased 37% to $85.5 million compared to $135.1 million in the prior year.

Risks

• The company's ability to continue as a going concern is a risk.
• The company's potential need to raise additional capital to fund operations is a risk.
• The company's ability to achieve or maintain profitability is a risk.
• Maintaining compliance with debt covenants is a risk.
• The company's ability to identify and develop successful new geographies, physician partners, payors and patients is a risk.
• Changes in market or industry conditions, regulatory environment, and competitive conditions are risks.
• The impact of fluctuations in risk adjustments is a risk.
• The company's ability to establish and maintain effective internal controls is a risk.
• Increased labor costs and medical expense are risks.
• The company's ability to recruit and retain qualified team members and independent physicians is a risk.

Future Outlook

The company is guiding for 2025 total revenues between $1.35 billion and $1.50 billion, medical margin between $174 million and $210 million, and Adjusted EBITDA between $(35) million and $5 million.

Management Comments

• Our business model remains fundamentally strong as we continue to deliver member and top-line growth, quality outcomes, and provider retention, said Aric Coffman, CEO of P3.
• With the $130M+ in identified programmatic opportunities advancing our path to financial sustainability, we remain committed to enabling our payor and provider partners to drive high quality, cost-efficient care and long-term market growth.

Industry Context

The announcement reflects the ongoing challenges and opportunities in the population health management sector, where companies are striving to balance growth with profitability amid evolving healthcare dynamics.

Comparison to Industry Standards

• The company's revenue growth of 18% is a positive sign, but the increasing net losses and adjusted EBITDA losses raise concerns about its operational efficiency compared to industry peers.
• Companies like Oak Street Health and Agilon Health, which also operate in the value-based care space, are often benchmarked against metrics like medical cost ratio and membership growth.
• P3 Health Partners' medical margin PMPM of $75 is lower than some of its competitors, indicating potential areas for improvement in managing medical expenses.

Stakeholder Impact

• Shareholders may be concerned about the increasing net losses and the potential need for additional capital.
• The company's ability to improve patient outcomes and lower costs will impact its relationships with payors and providers.
• Employees may be affected by potential cost-cutting measures or restructuring efforts.

Next Steps

• Management will host a conference call and webcast on March 27, 2025, at 4:30 PM ET to discuss the results.
• The company will focus on executing its strategic improvement opportunities to achieve financial sustainability.

Key Dates

Keywords

financial results, revenue, EBITDA, membership, healthcare, P3 Health Partners